Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Cyclophosphamide 13fludarabine 11Mycophenolic Acid 9Busulfan 8fludarabine phosphate 7Tacrolimus 7pirtobrutinib 6Whole-Body Irradiation 6Rituximab 6Melphalan 6Imatinib Mesylate 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4venetoclax 3nilotinib 3lintuzumab 3Stem Cell Transplantation 3Sirolimus 3Platelet Transfusion 3Methotrexate 3Cytarabine 3Cyclosporine 3Alemtuzumab 3vosaroxin 2ruxolitinib 2ibrutinib 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × R-CHOP protocol × Other hematologic neoplasm × Clear all
NCT04243434 2020-04-16

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Acrotech Biopharma Inc.

Phase 1 Unknown
56 enrolled
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡